Evaluation of the safety of cantastim in normal humans.
CANTASTIM, a good immunomodulatory agent obtained from a highly pathogenic strain of Pseudomonas aeruginosa was inoculated during 12 weeks in 21 healthy individuals aged 18-45 years. The subjects were clinically and laboratory investigated for body weight, antibodies against DNA, collage, cardiolipin, number of blood cells, blood and urine enzymes etc. After this intensive therapy, all the studied parameters were found in normal range of values. The results are a proof that this immunomodulator is not antigenic and has not side effects.
Olinescu
A
A
Cantacuzino Institute, Bucharest, Romania.
Radu
L D
LD
Dolganiuc
A
A
Istrate
N
N
Muni
I A
IA
D000276:Adjuvants, Immunologic / Q000009:adverse effects* / Q000494:pharmacology; D000293:Adolescent; D000328:Adult; D000942:Antigens, Bacterial / Q000009:adverse effects*; D001323:Autoantibodies / Q000096:biosynthesis; D015551:Autoimmunity / Q000187:drug effects; D001772:Blood Cell Count / Q000187:drug effects; D001798:Blood Proteins / Q000032:analysis; D001835:Body Weight / Q000187:drug effects; D004341:Drug Evaluation; D004798:Enzymes / Q000652:urine; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D010743:Phospholipids; D011550:Pseudomonas aeruginosa / Q000276:immunology*
D000276:Adjuvants, Immunologic; D000942:Antigens, Bacterial; D001323:Autoantibodies; D001798:Blood Proteins; D004798:Enzymes; D010743:Phospholipids; C049675:cantastim